Shares of Boston Scientific Corp. (NYSE:BSX) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $23.61 and last traded at $23.59, with a volume of 6,331,355 shares traded. The stock had previously closed at $23.30.

A number of analysts have recently issued reports on BSX shares. Goldman Sachs Group Inc. increased their price objective on shares of Boston Scientific Corp. from $21.00 to $22.00 in a research note on Friday, April 8th. Needham & Company LLC increased their price objective on shares of Boston Scientific Corp. from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, April 27th. Evercore ISI increased their price objective on shares of Boston Scientific Corp. from $21.50 to $23.50 and gave the stock a “buy” rating in a research note on Wednesday, April 27th. Benchmark Co. reissued a “buy” rating and issued a $22.00 price objective (up from $20.00) on shares of Boston Scientific Corp. in a research note on Wednesday, April 27th. Finally, Zacks Investment Research raised shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a research note on Tuesday, April 12th. Four investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.44.

The firm’s market capitalization is $32.10 billion. The company’s 50 day moving average is $22.80 and its 200-day moving average is $19.70.

Boston Scientific Corp. (NYSE:BSX) last issued its earnings results on Wednesday, April 27th. The company reported $0.28 EPS for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.04. The business earned $1.96 billion during the quarter, compared to analyst estimates of $1.91 billion. Boston Scientific Corp.’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the company earned $0.21 earnings per share. Equities research analysts expect that Boston Scientific Corp. will post $1.09 earnings per share for the current year.

In other news, EVP Timothy A. Pratt sold 24,229 shares of the stock in a transaction dated Wednesday, June 1st. The shares were sold at an average price of $22.66, for a total value of $549,029.14. Following the completion of the sale, the executive vice president now directly owns 301,724 shares in the company, valued at $6,837,065.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Kevin J. Ballinger sold 111,807 shares of the stock in a transaction dated Wednesday, April 27th. The shares were sold at an average price of $21.62, for a total transaction of $2,417,267.34. Following the completion of the sale, the senior vice president now owns 83,600 shares of the company’s stock, valued at $1,807,432. The disclosure for this sale can be found here.

Several large investors have modified their holdings of the stock. Tredje AP fonden boosted its stake in shares of Boston Scientific Corp. by 1.3% in the fourth quarter. Tredje AP fonden now owns 86,021 shares of the company’s stock worth $1,586,000 after buying an additional 1,138 shares during the period. Comerica Bank raised its stake in shares of Boston Scientific Corp. by 0.4% in the fourth quarter. Comerica Bank now owns 333,885 shares of the company’s stock worth $5,820,000 after buying an additional 1,206 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of Boston Scientific Corp. by 1.8% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 87,889 shares of the company’s stock worth $1,621,000 after buying an additional 1,540 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Boston Scientific Corp. by 7.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 57,502 shares of the company’s stock worth $1,061,000 after buying an additional 3,945 shares in the last quarter. Finally, Advantus Capital Management Inc raised its stake in shares of Boston Scientific Corp. by 3.7% in the fourth quarter. Advantus Capital Management Inc now owns 130,685 shares of the company’s stock worth $2,410,000 after buying an additional 4,604 shares in the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.